<abstract xmlns="http://www.w3.org/1999/xhtml"><p> The results of treatment of patients with arterial hypertension and obesity combined with non-alcoholic steatohepatitis are presented in article. Herein, the combined use of olmesartan or telmisartan with atorvastatin for 12 weeks had a positive impact on the physical condition of patients with arterial hypertension and obesity. This effect was manifested by maintenance of optimal blood pressure, the reduction of subjective complaints and the improvement of heart hemodynamics. Administration of sartans and statins to patients with arterial hypertension combined with obesity and non-alcoholic steatohepatitis led to a significant reduction of LDL (p&lt;0.01) and LDL cholesterol levels (p&lt;0.01), as well as the values of leptin (p&lt;0.01) and IL-6 (p&lt;0.01). The combination of olmesartan or telmisartan with atorvastatin not only allows a control of BP, but also a reduction of the pro-atherogenic fractions of blood lipids, hyperleptinaemia and levels of pro-inflammatory IL-6, hence, in this manner, improving the patient general condition.</p></abstract>

The results of treatment of patients with arterial hypertension and obesity combined with non-alcoholic steatohepatitis are presented in article. Herein, the combined use of olmesartan or telmisartan with atorvastatin for 12 weeks had a positive impact on the physical condition of patients with arterial hypertension and obesity. This effect was manifested by maintenance of optimal blood pressure, the reduction of subjective complaints and the improvement of heart hemodynamics. Administration of sartans and statins to patients with arterial hypertension combined with obesity and non-alcoholic steatohepatitis led to a significant reduction of LDL (p<0.01) and LDL cholesterol levels (p<0.01), as well as the values of leptin (p<0.01) and IL-6 (p<0.01). The combination of olmesartan or telmisartan with atorvastatin not only allows a control of BP, but also a reduction of the pro-atherogenic fractions of blood lipids, hyperleptinaemia and levels of pro-inflammatory IL-6, hence, in this manner, improving the patient general condition.

Leptin and interleukin-6 level in patients with hypertension and obesity combined with non-alcoholic steatohepatitis during treatment with sartans and statins

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

The results of treatment of patients with arterial hypertension and obesity combined with non-alcoholic steatohepatitis are presented in article. Herein, the...

Leptin and interleukin-6 level in patients with hypertension and obesity combined with non-alcoholic steatohepatitis during treatment with sartans and statins

Pubblicato online: 25 ott 2017

Pagine: 57 - 60

Ricevuto: 14 feb 2017

Accettato: 24 mag 2017

DOI: https://doi.org/10.1515/cipms-2017-0011

Parole chiave
arterial hypertension, obesity, non-alcoholic steatohepatitis, olmesartan, telmisartan, atorvastatin

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Leptin and interleukin-6 level in patients with hypertension and obesity combined with non-alcoholic steatohepatitis during treatment with sartans and statins

Pubblicato online: 25 ott 2017

Pagine: 57 - 60

Ricevuto: 14 feb 2017

Accettato: 24 mag 2017

DOI: https://doi.org/10.1515/cipms-2017-0011

Parole chiavearterial hypertension, obesity, non-alcoholic steatohepatitis, olmesartan, telmisartan, atorvastatin

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Parole chiave
arterial hypertension, obesity, non-alcoholic steatohepatitis, olmesartan, telmisartan, atorvastatin